CCSD code A7620 – Thoracic sympathectomy neurolysis

Key takeaways

CCSD Code A7620 covers thoracic sympathectomy with a neurolytic agent, performed under X-ray (fluoroscopy) control.

A diagnostic block with local anesthetic bills as A7520, and open or thoracoscopic resection takes a surgical code.

Fluoroscopy is written into the A7620 descriptor, so a procedure without documented X-ray control can’t be billed under it.

UK private insurers typically require pre-authorization, a confirmed refractory diagnosis and a recognized consultant before the procedure.

Practice management software like Pabau checks for membership numbers and authorization codes before an A7620 claim reaches the insurer.

What is CCSD Code A7620?

CCSD Code A7620 is the CCSD coding schedule entry for a therapeutic thoracic sympathectomy, performed with a neurolytic agent under X-ray control. The consultant injects phenol or ethanol into the thoracic sympathetic chain under fluoroscopy to interrupt the nerves for the long term.

Two neighboring procedures often get confused with it. A diagnostic sympathetic block uses local anesthetic to test whether the nerve drives the patient’s symptoms, and it bills as A7520. Surgical sympathectomy, an open or thoracoscopic resection of the chain, falls under a separate CCSD code.

A7620 sits in the Sympathetic Nerves category of Chapter 3, “Spine, spinal cord and peripheral nerves,” at the Major complexity band. UK private medical insurers reimburse it when a recognized consultant performs it, typically a pain medicine specialist, anesthetist or thoracic surgeon. The setting must be a private hospital or day-case unit regulated by the Care Quality Commission (CQC) in England.

The procedure behind A7620

A7620 covers chemical ablation of the thoracic sympathetic chain, typically at one or more levels between T2 and T5. The consultant guides a needle under fluoroscopy to the paravertebral gutter beside the sympathetic ganglia. A neurolytic agent is then injected to interrupt sympathetic tone for the long term.

The operative note needs to record each of these steps:

1. Patient positioning and skin preparation under sterile conditions
2. Fluoroscopy used to identify the target vertebral level and needle trajectory
3. Needle placement confirmed under live X-ray imaging in two planes
4. Contrast injection (where used) to confirm needle position before the neurolytic agent is given
5. Injection of the neurolytic agent (phenol or ethanol, with volume and concentration documented)
6. Needle withdrawal and post-procedure assessment of sympathetic effect

Each step feeds the documentation behind a valid A7620 claim. If the note skips fluoroscopy or omits the agent and its volume, the insurer has grounds to query or deny the claim. A procedure note template with a required field for each step stops those omissions at the source.

Indications for thoracic sympathectomy

Private insurers expect the clinical indication to be documented before they authorize A7620. The British Pain Society and published pain medicine literature support these indications for thoracic neurolytic sympathectomy:

• Hyperhidrosis (palmar and axillary): the most common indication in private practice. Patients with severe, refractory primary hyperhidrosis who have failed topical aluminum chloride, iontophoresis and botulinum toxin may be offered sympathectomy as a definitive option. Insurers typically require documented failure of at least two conservative measures.
• Complex regional pain syndrome (CRPS) of the upper limb: used in carefully selected patients whose sympathetically maintained pain has been confirmed by a diagnostic block. Insurers routinely ask for evidence of benefit from that diagnostic block before authorizing the neurolytic procedure.
• Vascular insufficiency of the upper limb: including Raynaud’s phenomenon that doesn’t respond to vasodilator therapy, where sympathetic vasoconstriction is a contributing factor.
• Refractory angina: in patients who aren’t candidates for revascularization and whose angina has a sympathetically mediated component. This indication requires cardiology corroboration.

Before granting pre-authorization, insurers commonly ask for a GP or specialist referral letter, confirmation of the diagnosis, and evidence that conservative options have been exhausted.

Why X-ray control decides whether A7620 applies

The phrase “under X-ray control” is written into the official A7620 descriptor, so fluoroscopy guidance is a condition of the code. A thoracic sympathectomy performed without X-ray imaging can’t be billed as A7620.

That wording creates three billing risks to manage:

• Imaging not documented: the procedure used fluoroscopy, but the operative note doesn’t say so. The insurer’s medical reviewer can’t assume imaging was used, so the claim may be downgraded or rejected.
• CT guidance used instead: some pain units use CT guidance for complex cases. The CCSD descriptor points to fluoroscopy, so discuss coding with the insurer before submitting A7620 for a CT-guided procedure.
• Ultrasound-only approach miscoded: ultrasound-guided sympathetic blocks exist, but they don’t meet the A7620 descriptor. Billing A7620 for one is a miscoding error.

The safest approach is one explicit statement in the operative note. For example: “The procedure was performed under continuous fluoroscopic guidance. Needle position was confirmed under X-ray control before injection.” That wording answers the most common documentation query on A7620 claims before the insurer raises it.

How to bill CCSD Code A7620

Billing A7620 in a UK private practice follows the same sequence every time. Getting each step right before the procedure prevents most claim delays.

Prior authorization: what insurers require before A7620

All four major UK private medical insurers typically require pre-authorization before a neurolytic sympathectomy. Typical requirements from Bupa, AXA Health, Aviva and Vitality Health include:

• A GP or specialist referral letter confirming the diagnosis and failed conservative treatment
• Evidence of a prior diagnostic sympathetic block with a documented clinical response (for CRPS indications)
• Consultant recognition: most insurers require a consultant anesthetist or pain medicine specialist, not an associate specialist or SAS-grade doctor without insurer recognition
• Facility recognition: the insurer must recognize the treating hospital or day-case unit
• An authorization reference number, which must appear on the A7620 invoice

Authorization requirements vary by insurer and change periodically. Treat this list as typical practice rather than policy, and confirm current rules with each insurer before the procedure date.

Documentation requirements for A7620

The operative note submitted with an A7620 claim should confirm each element below. An invoice without supporting documentation is a common cause of delayed payment or outright denial.

• Procedure performed: thoracic sympathectomy, with the level or levels specified (for example, T3)
• Nature of the procedure: therapeutic neurolytic, not diagnostic
• Imaging: fluoroscopy used, with needle position confirmed under X-ray control
• Neurolytic agent: name (phenol or ethanol), concentration and volume injected
• Indication: the documented clinical reason, such as refractory palmar hyperhidrosis or CRPS of the right upper limb
• Conservative measures tried: a brief statement confirming prior treatment failure
• Patient consent: written consent obtained before the procedure
• Post-procedure assessment: confirmation of sympathetic effect and any immediate complications

Digital clinical forms can make each of these fields mandatory before the note is finalized. That matters most in high-volume interventional pain units, where documentation errors build up quickly.

Related and neighboring CCSD codes

A7620 belongs to a family of CCSD codes for neurolytic and sympathetic nerve procedures. Knowing the adjacent codes reduces unbundling errors and prevents upcoding or downcoding.

Codes commonly confused with A7620

Three coding errors come up repeatedly in A7620 billing audits:

• Diagnostic sympathetic block billed as A7620: a diagnostic block uses local anesthetic only, to check whether a nerve is generating pain. It has no lasting effect, and it bills as A7520. Insurers compare the procedure note against the submitted code. If the note says “local anesthetic” and names no neurolytic agent, A7620 will be queried or denied.
• Surgical thoracoscopic sympathectomy coded as A7620: endoscopic or open resection of the sympathetic chain is a surgical procedure with its own CCSD code. A7620 covers the chemical neurolysis approach only.
• Repeated diagnostic block series coded as cumulative neurolysis: several diagnostic blocks don’t add up to a therapeutic neurolytic procedure. They can’t be billed as A7620 after the fact.

The decision below runs both tests from the operative note, the agent injected and the imaging used, before you commit to a code.

Common claim denials for CCSD Code A7620

A7620 claims are denied for a predictable set of reasons, and each one is preventable with a pre-procedure checklist.

Appeals against A7620 denials usually succeed when the denial is about documentation rather than eligibility. Keep supporting documents, authorization references and imaging reports in the patient record, so they can go out with an appeal without delay.

How Pabau prevents A7620 claim denials

Many private practices still prepare A7620 invoices by hand, copying authorization references and consultant details from emails and paper notes. Each copy is a chance for a transcription error or a missing attachment, and the insurer sends the claim back.

Practice management software like Pabau links each patient to their insurer and pulls the membership number and authorization code into the invoice. Its medical claims management tools send the claim through Healthcode or by email, straight from the patient record.

Before a claim goes out, Pabau runs validation checks for the details insurers need, like membership numbers and authorization codes. If something’s missing, Pabau flags it before the claim is sent. A typical A7620 billing workflow in Pabau runs in five steps:

1. Create the patient record and confirm insurer membership and the authorization reference before the procedure date
2. Attach the pre-authorization confirmation and referral letter to the patient file
3. After the procedure, raise the CCSD-coded invoice with A7620, the consultant, the facility and the procedure date
4. Attach the operative note and imaging report to the claim
5. Send the claim to the insurer through Healthcode or by email, then track it from pending to paid

Keeping the clinical documentation and the billing record together makes appeals simpler if a claim is queried. That helps most when one consultant performs A7620 for several insurers with different submission rules.

Manage CCSD billing and insurer claims in one place

Raise CCSD-coded invoices for A7620, attach the operative note and authorization, and send claims to UK insurers through Healthcode without leaving Pabau.

Book a demo

Conclusion

A7620 pays reliably for the practices that settle the code before the needle goes in. Confirm the agent, the imaging and the authorization reference at booking, and the operative note becomes a formality instead of a rescue job.

The cost is a few minutes of setup per note template and per insurer. Skip it, and each denied claim costs a resubmission, an appeal letter and a delayed payment.

Book a demo to see how Pabau checks A7620 claims for missing authorization codes before they reach Bupa, AXA Health, Aviva or Vitality.

Continue your research

Billing A7620 to Bupa? Bupa CCSD codes covers Bupa’s code requirements, consultant recognition and submission expectations in one place.

Checking what Bupa pays for a CCSD code? Bupa procedure codes fee schedule explains how Bupa sets reimbursement for covered procedures.

Comparing billing systems for a UK practice? Best medical billing software in the UK ranks the platforms that handle insurer claims for private practices.

Frequently asked questions